Condition
Partial Lipodystrophy
Total Trials
5
Recruiting
3
Active
4
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 2 (2)
P 3 (1)
P 4 (1)
Trial Status
Recruiting3
Active Not Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05470504Phase 2Recruiting
Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance
NCT02325674Recruiting
MEASuRE: Metreleptin Effectiveness And Safety Registry
NCT05164341Phase 3Active Not RecruitingPrimary
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
NCT06484868Phase 4RecruitingPrimary
Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
NCT00896298Phase 2Completed
Trial of Leptin Replacement Therapy in Patients With Lipodystrophy
Showing all 5 trials